The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from ...

Harvey Jones loves his FTSE 100 dividend income shares but was disappointed by the lack of growth. Now it looks like that may ...

AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic ...

The FTSE 100 headed lower as trading got underway on Friday, in line with a drop for heavyweights AstraZeneca PLC (LON: AZN) ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.

Find insight on BCE, Siemens Healthineers, WeChat, Apple, U.S. tariffs and more in the latest Market Talks covering ...

AstraZeneca's strong results boosted the FTSE 100 to a record close, aided by the Bank of England's rate cut. The BoE's ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

European shares closed at an all-time high on Thursday, with mining companies in the lead following a raft of upbeat earnings ...

Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...